Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Binds aggregated soluble and insoluble amyloid beta, including oligomers and fibrils, promoting reduction of amyloid plaque burden. This is the pharmacological rationale; clinical benefit was not established to the level required for continued approval.
Indications / reported uses
Historical US indication: treatment of Alzheimer disease initiated in patients with mild cognitive impairment or mild dementia stage, following confirmation of amyloid pathology. Aduhelm was withdrawn from clinical use and its US approval was withdrawn on 1 November 2024; it is not a current treatment option.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Aducanumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Aducanumab Permitted Daily Exposure (PDE) report (the Aducanumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Aducanumab Occupational Exposure Limit (OEL) report (the Aducanumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.